Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7732430 | MAYNE PHARMA | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
Mar, 2025
(1 year, 8 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 15, 2026 |
NCE-1 date: 2025-04-15
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET;ORAL
17
European Union
14
Netherlands
9
Canada
9
United States
7
Germany
7
Spain
6
Denmark
6
Austria
6
Portugal
1
ME
1
Yugoslavia
1
Poland
1
Korea, Republic of
1
Ukraine
1
Luxembourg
1
Brazil
1
Hong Kong
1
Costa Rica
1
Turkey
1
China
1
Japan
1
Belgium
1
Hungary
1
Mexico
1
New Zealand
1
EA
1
Australia
1
Norway
1
South Africa
1
Ecuador
1
Israel
1
Cyprus
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic